trending Market Intelligence /marketintelligence/en/news-insights/trending/5Is_bkM7p6BwTwfE6fTSPw2 content esgSubNav
In This List

ADMA Biologics closes Biotest asset acquisition

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


ADMA Biologics closes Biotest asset acquisition

ADMA Biologics Inc. closed its acquisition of the assets of Biotest AG unit Biotest Pharmaceuticals Corp.'s therapy business unit.

The assets included in the transaction are two U.S. Food and Drug Administration licensed products, Nabi-HB and Bivigam, along with the manufacturing and testing operations of two Boca Raton, Fla.-based facilities.

ADMA Biologics also received $27.5 million in cash, with $15 million in the form of a subordinated loan from Biotest, and an additional $12.5 million commitment from Biotest to invest in future ADMA equity financings.

Following the completion of the deal, ADMA has assumed operational control of the assets and formally started the integration activities.